Next Article in Journal
CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
Previous Article in Journal
Available Technologies, Applications and Benefits of Teleorthodontics. A Literature Review and Possible Applications during the COVID-19 Pandemic
Open AccessReview

Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?

1
Department of Experimental Oncology, Istituto Europeo di Oncologia IRCCS, Via Adamello 16, 20 139 Milan, Italy
2
Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20 122 Milan, Italy
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 1892; https://doi.org/10.3390/jcm9061892
Received: 11 May 2020 / Revised: 11 June 2020 / Accepted: 15 June 2020 / Published: 17 June 2020
(This article belongs to the Section Hematology)
Drug repurposing is a method of drug discovery that consists of finding a new therapeutic context for an old drug. Compound identification arises from screening of large libraries of active compounds, through interrogating databases of cell line gene expression response upon treatment or by merging several types of information concerning disease–drug relationships. Although, there is a general consensus on the potential and advantages of this drug discovery modality, at the practical level to-date no non-anti-cancer repurposed compounds have been introduced into standard acute myeloid leukaemia (AML) management, albeit that preclinical validation yielded several candidates. The review presents the state-of-the-art drug repurposing approach in AML and poses the question of what has to be done in order to take a full advantage of it, both at the stage of screening design and later when progressing from the preclinical to the clinical phases of drug development. We argue that improvements are needed to model and read-out systems as well as to screening technologies, but also to more funding and trust in drug repurposing strategies. View Full-Text
Keywords: acute myeloid leukaemia; drug repurposing; candidate compounds acute myeloid leukaemia; drug repurposing; candidate compounds
Show Figures

Graphical abstract

MDPI and ACS Style

Valli, D.; Gruszka, A.M.; Alcalay, M. Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia? J. Clin. Med. 2020, 9, 1892.

AMA Style

Valli D, Gruszka AM, Alcalay M. Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia? Journal of Clinical Medicine. 2020; 9(6):1892.

Chicago/Turabian Style

Valli, Debora; Gruszka, Alicja M.; Alcalay, Myriam. 2020. "Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?" J. Clin. Med. 9, no. 6: 1892.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop